Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A.
Barley K, et al. Among authors: sanchez l, sanchez gm.
Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22.
Am J Hematol. 2020.
PMID: 31814152
Free article.
Clinical Trial.
No abstract available.